Biotechnology Japanese drug major Chugai Pharmaceutical has filed a new drug application to the Ministry of Health, Labor and Welfare (MHLW), for glycoengineered type II anti-CD20 monoclonal antibody, obinutuzumab (genetical recombination) which was co-developed with Nippon Shinyaku for the treatment of “CD20-positive B-cell follicular lymphoma (FL) in Japan. 24 August 2017